In Reply to 'Verinurad/Febuxostat and Nephrotoxicity'

Affiliations

¹ Department of Nephrology, University Hospital, Limerick & Health Research Institute, University of Limerick, Limerick, Ireland.
² AstraZeneca R&D, Gothenburg, Sweden.
³ VAHCS and University of California, San Diego, CA.

Comment

Austin G Stack et al. Am J Kidney Dis. 2021 Sep.

. 2021 Sep;78(3):468-469.

doi: 10.1053/j.ajkd.2021.05.009. Epub 2021 Jun 11.

¹ Department of Nephrology, University Hospital, Limerick & Health Research Institute, University of Limerick, Limerick, Ireland.
² AstraZeneca R&D, Gothenburg, Sweden.
³ VAHCS and University of California, San Diego, CA.

No abstract available

Comment on

Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Stack AG, Dronamraju N, Parkinson J, Johansson S, Johnsson E, Erlandsson F, Terkeltaub R. Stack AG, et al. Am J Kidney Dis. 2021 Apr;77(4):481-489. doi: 10.1053/j.ajkd.2020.09.009. Epub 2020 Oct 29. Am J Kidney Dis. 2021. PMID: 33130235 Free PMC article. Clinical Trial.
Verinurad/Febuxostat and Nephrotoxicity.
Fernandez-Prado R, Ortiz A. Fernandez-Prado R, et al. Am J Kidney Dis. 2021 Sep;78(3):468. doi: 10.1053/j.ajkd.2021.03.029. Epub 2021 Jun 11. Am J Kidney Dis. 2021. PMID: 34126127 No abstract available.